BHIVA guidelines for the management of hepatitis viruses in adults infected with HIV 2013 (updated September 2014)

BHIVA guidelines for the management of hepatitis viruses in adults infected with HIV 2013 Introduction

The purpose of these guidelines is to provide guidance on best clinical practice in the treatment and management of adults with HIV and viral hepatitis coinfection. The scope includes: i) guidance on diagnostic and fibrosis screening; ii) preventative measures including immunisation and behavioural intervention; iii) ARV therapy and toxicity; iv) management of acute and chronic HBV/HIV and HCV/HIV; v) monitoring and management of coinfection-related end-stage liver disease (ESLD) including transplantation; and vi) discussion on HDV/HIV and HEV/HIV infection. The guidelines are aimed at clinical professionals involved in and responsible for the care of adults with HIV and viral hepatitis coinfection, and at community advocates responsible for promoting the best interests and care of adults with coinfection. They should be read in conjunction with other published BHIVA and hepatitis guidelines.
 

Downloads

BHIVA guidelines for the management of hepatitis viruses in adults infected with HIV 2013 NHS Evidence accredited provider


Update - October 2015

Please note that the BHIVA guidelines for the management of hepatitis viruses in adults infected with HIV 2013 are now out of date. An updated version of these guidelines is currently being worked on and is planned for release in 2016.


Update - September 2014

Since the BHIVA guidelines for the management of hepatitis viruses in adults infected with HIV were published in January 2014, new data have been presented confirming the benefits of individual direct-acting antivirals (DAAs) with pegylated interferon (PEG) and ribavirin (RBV) and in combination in interferon-sparing regimens for the treatment of chronic hepatitis C (HCV). Several of these have now received European approval and other drugs are likely to be approved later in 2014 or in 2015. This update to the guidelines reflects the current situation and is intended to assist those involved in the management of chronic HCV/HIV co-infection, including patients, in making decisions on treatment. Updates to this guideline will be provided as and when new data become available.
Consensus statement on the guidelines for treating hepatitis C in patients with HIV (update September 2014) NHS Evidence accredited provider


Update - June 2014

Green highlights denote changes that have been made to the document post-publication for society reference only.
For citation purposes readers should refer to the original text (see above). The version below was produced in June 2014, with most recent amendments highlighted in green.
BHIVA guidelines for the management of hepatitis viruses in adults infected with HIV 2013 (updated June 2014) NHS Evidence accredited provider


Appendices for these guidelines

Download Appendix 1
Download Appendix 2

Consultation Comments
Download the comments received by the BHIVA Secretariat during the web consultation process

Presentation
Presentation on these guidelines is available to download and use to facilitate dissemination and implementation of the BHIVA guidance.
Download the PDF
Download the Powerpoint Presentation
 

Writing Group

Dr Ed Wilkins (Chair), Dr Mark Nelson (Vice Chair), Dr Kosh Agarwal, Ms Dola Awoyemi, Dr Eleanor Barnes, Dr Sanjay Bhagani, Dr Gary Brook, Dr Ashley Brown, Ms Sheena Castelino, Dr Graham Cooke, Prof Martin Fisher, Prof Anna Maria Geretti, Mr Robert James, Dr Ranjababu Kulasegaram, Prof Clifford Leen, Prof David Mutimer, Dr Chloe Orkin, Dr Emma Page, Dr Adrian Palfreeman, Dr Padmasayee Papineni, Dr Alison Rodger, Dr CY William Tong
 

Guidelines updates and date of next review

The guidelines will be reviewed and updated as required on a 6-monthly basis with a plan for an extensive rewrite in 2016. The Writing Group will continue to meet regularly to consider new information from high-quality studies an publish amendments and addendums to the current recommendations before the full revision date where this is thought to be clinically important to ensure continued best practice.
 

Reference

HIV Medicine (2013), 14 (Suppl. 4), 1–71.